|
Divarasib Clinical Trials
5 actively recruiting trials across 3 locations
No change since May 2026
Also known as: GDC-6036, RO7435846
Pipeline
Phase 1: 1Phase 2: 1Phase 3: 2Phase 1/2: 1
Top Sponsors
- Hoffmann-La Roche4
- Genentech, Inc.1
Indications
- Cancer5
- Lung Cancer3
- Non Small Cell Lung Cancer3
- KRAS G12C Lung Cancer1
- Metastatic Colorectal Cancer1
Duarte, California2 trials
A Study Evaluating the Safety, Activity, and Pharmacokinetics of Divarasib as a Single Agent or in Combination With Other Anti-Cancer Therapies in Participants With Previously Untreated Advanced or Metastatic Non-Small Cell Lung Cancer With a KRAS G12C Mutation
City of Hope National Medical Center
Phase 1/2
A Study of Multiple Therapies in Biomarker-selected Participants With Resectable Stages IB-III Non-small Cell Lung Cancer (NSCLC)
City of Hope Comprehensive Cancer Center
Phase 2
Other1 trial
Birmingham, Alabama1 trial
A Study Evaluating the Safety and Efficacy of Targeted Therapies in Subpopulations of Patients With Metastatic Colorectal Cancer (INTRINSIC)
UAB Comprehensive Cancer Center
Phase 1
Anchorage, Alaska1 trial
A Study Evaluating the Efficacy and Safety of Divarasib and Pembrolizumab Versus Pembrolizumab and Pemetrexed and Carboplatin or Cisplatin in Participants With Previously Untreated, KRAS G12C-Mutated, Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer
Alaska Oncology and Hematology
Phase 3
Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.
This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.